News Release 

Insilico Medicine to present new results in generative biology AI

InSilico Medicine


IMAGE: Insilico Medicine to present at the 38th JP Morgan Healthcare Conference. view more 

Credit: Insilico Medicine

Friday, January 10, 2020 - Insilico Medicine, a biotechnology company developing end-to-end drug discovery pipelines utilizing the next-generation artificial intelligence, to present new results of its generative biology pipeline resulting in novel targets in liver disease.

The company will showcase the results of the first experimental validation of its generative biology target ID system at CTIC on the 12th of January, 2020 and at Biotech Showcase, 13th of January, 2020.

"For the first time, we will present the results of our generative biology pipeline resulting in novel targets for liver disease during the JP Morgan. This is a major milestone for us, and we are happy to continue making history in AI-powered biomedicine," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.

You can also meet Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine at FierceBiotech Executive Breakfast on the 14th of January, 2020.


For further information, images or interviews, please contact:

Contact: Klug Gehilfe

About Insilico Medicine

Insilico Medicine is an artificial intelligence company with offices in six countries and regions striving to accelerate three areas of drug discovery and development: disease target identification, generation of novel molecules (generative chemistry) and synthetic biological data (generative biology), and prediction of clinical trial outcomes. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas. Recently, Insilico Medicine published a proof-of-concept study in generative chemistry in Nature Biotechnology, and secured $37 million in series B funding.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.